![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by Rick on June 12, 2000, at 1:00:54
(Interesting findings! My apologies if someone's already posted this.)J Clin Psychiatry 2000 May;61(5):378-81
"Modafinil augmentation of antidepressant treatment in depression"Menza MA, Kaufman KR, Castellanos A
Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854, USA. menza@umdnj.edu
[Medline record in process]
BACKGROUND: Despite a relative lack of controlled data, stimulants are often used to augment antidepressant treatment in patients who have had only a partial response to first-line therapy. Modafinil is a novel psychostimulant that has shown efficacy in, and was recently marketed for, treating excessive daytime sleepiness associated with narcolepsy. The mechanism of action of modafinil is unknown, but, unlike other stimulants, the drug is highly selective for the central nervous system, has little effect on dopaminergic activity in the striatum, and appears to have a lower abuse potential. METHOD: In this retrospective case series, we describe 7 patients with DSM-IV depression (4 with major depression and 3 with bipolar depression) for whom we used modafinil to augment a partial or nonresponse to an antidepressant. The Hamilton Rating Scale for Depression was administered as part of routine clinical practice prior to treatment and at each subsequent visit. RESULTS: At doses of 100 to 200 mg/day, all 7 patients achieved full or partial remission, generally within 1 to 2 weeks. All patients had some residual tiredness or fatigue prior to starting modafinil, and this symptom was particularly responsive to augmentation. Side effects were minimal and did not lead to discontinuation of the drug in any of the patients. CONCLUSION: Modafinil appears to be a drug with promise as an augmenter of antidepressants, especially in patients with residual tiredness or fatigue. It is a particularly attractive alternative to other stimulants because of its low abuse potential and Schedu
Posted by Rick on June 12, 2000, at 1:10:15
In reply to News on Provigil(modafinil) augmentation of AD's , posted by Rick on June 12, 2000, at 1:00:54
(My posting curse continues, with the last three words of the abstract getting clipped. I've reprinted the entire Conclusion section below. Now THIS has GOT to be short enough to make it through in toto!)
CONCLUSION: Modafinil appears to be a drug with promise as an augmenter of antidepressants, especially in patients with residual tiredness or fatigue. It is a particularly attractive alternative to other stimulants because of its low abuse potential and Schedule IV status.
Posted by SLS on June 12, 2000, at 9:56:22
In reply to Re: News on Provigil(modafinil) augmentation of AD's , posted by Rick on June 12, 2000, at 1:10:15
>
> (My posting curse continues, with the last three words of the abstract getting clipped. I've reprinted the entire Conclusion section below. Now THIS has GOT to be short enough to make it through in toto!)
>
>
> CONCLUSION: Modafinil appears to be a drug with promise as an augmenter of antidepressants, especially in patients with residual tiredness or fatigue. It is a particularly attractive alternative to other stimulants because of its low abuse potential and Schedule IV status.
Dear Rick,Thanks again for this citation.
I just sent off an e-mail containing this text to my doctor. I'd be pretty pissed if he didn't know about it already, as he is one of the department heads at UMDNJ.
- Scott
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.